HEPA News and Press, Hepion Pharmaceuticals Inc. From 01/06/22

EDISON, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...

EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...

EDISON, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...

Hepion Pharmaceuticals (NASDAQ:HEPA) announces that the FDA has accepted its investigational new drug (IND) application for CRV431, a liver-targeting, novel cyclophilin inhibitor, for the treatment of hepatocellular carcinoma (HCC). Shares up 1.7% premarket at $1.23. On July 29, 201...

- New IND Expands Liver Disease Pipeline for CRV431 - - IND Clearance Allows CRV431 to Move Directly into Phase 2 for Hepatocellular Carcinoma Treatment - - New IND Provides for Complementary Therapeutic Approach of Treating NASH and Liver Cancer with a Single Once-a-Day...

The U.S. Food and Drug Administration granted fast track designation to Hepion Pharmaceuticals (HEPA) lead drug candidate CRV431 to treat non-alcoholic steatohepatitis (NASH), a type of liver disease. “CRV431 has been investigated in healthy subjects during our Phase 1 program, an...

Cumberland Pharmaceuticals CPIX +90% on FDA label expansion for pain therapy Pioneer Power Solutions (NASDAQ:PPSI) +66%. First Wave BioPharma (NASDAQ:FWBI) +53% announces independent data monitoring committee provides positive interim safety assessment for part 2 COVID-19 RESER...

EDISON, N.J., Nov. 30, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...

Hepion Pharmaceuticals (NASDAQ:HEPA) announces the results of a nonclinical research study showing that CRV431 significantly decreased the growth of liver tumors in a mouse model of liver cancer. In this study, mouse hepatocellular cancer (HCC) cells were surgically implanted into livers of r...

EDISON, N.J., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH...